Treg Modulation With CD28 and IL-6 Receptor Antagonists
a study on Kidney Transplant
Living-Donor Kidney Transplant Kidney Transplant Recipients adult living-donor kidney transplant recipients novel immunosuppressive (IS) therapy regimen lulizumab pegol (BMS-931699) CD28 and IL-6 biologic blockade CD28 and IL-6 receptor antagonists T regulatory cells (Treg) modulation Mycophenolic Acid Prednisone Methylprednisolone Methylprednisolone Hemisuccinate Everolimus Abatacept Thymoglobulin Antilymphocyte Serum lulizumab pegol antithymocyte globulin (rabbit) tocilizumab belatacept mycophenolate mofetil lulizumab pegol + novel ISR
Lead Scientists at UCSF
- Flavio Vincenti, M.D.
I have been at UCSF since 1975 and on the faculty of the Department of Medicine in the division of Nephrology since 1976 and have been involved with the transplant service in patient care and clinical trials with novel immunosuppression drugs
- Sindhu Chandran, M.D.
A transplant nephrologist with expertise in kidney and pancreas transplantation, Dr. Chandran earned her medical degree at All India Institute of Medical Sciences, and completed her residency at the University of Arizona.
- accepting new patients
- Start Date
- Completion Date
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Allergy and Infectious Diseases Division of Allergy, Immunology, and Transplantation Clinical Trials in Organ Transplantation (CTOT)
- Phase 1/2
- Study Type
- Last Updated